Jagannadham Thununguntla, Strategist & Head of Research, SMC Global Securities told CNBC-TV18, "It is a clear exit in Ranbaxy Laboratories. The biggest strength for any pharma company is its credibility. Ranbaxy is clearly in crisis right now."
"I feel much downsides are coming, I think various regulators are going through various rounds of investigations and any bad news from any pocket can take the stock easily to Rs 250. It makes sense to exit immediately," he said. Also Read: Synriam developed by Ranbaxy wins Innovation Award
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
